OncoForma
PrivateLast Round
Grant
Mar 24, 2026
Total Funding Raised
$1.09M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
OncoForma is a biotechnology company that provides precision oncology diagnostic services by using patient-derived tumor organoids to test drug efficacy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OncoForma Comparables
Compare OncoForma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| First Ascent Biomedical | 84% | |
| SageMedic Corp. | 84% | |
| Invitrocue | 83% | |
OncoForma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 24, 2026 |
OncoForma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Saskatchewan Health Research Foundation | Grant |
| Genome Canada | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 24, 2026
$1.09M grant from Genome Canada and others.
OncoForma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about OncoForma's valuation, stock price, and market status.